ESPR vs HAL · rev $332.3M vs P/E 9.3, $19.05B cap
Esperion Therapeutics Inc (ESPR) versus Halliburton Company (HAL) — a side-by-side from cached financials, not a winner call.
Esperion Therapeutics Inc (ESPR) is a drug manufacturers - specialty & generic company listed on NASDAQ.
Halliburton Company (HAL) is a oil & gas equipment & services company listed on US.
Latest reported ESPR revenue for 2024-12-31 was $332.3M. Net income was -$51.7M. Revenue was up 185.7% from 2023-12-31 to 2024-12-31. ESPR currently screens at market cap $816.9M.
HAL does not have a complete income-statement cache yet.
ESPR currently screens at market cap $816.9M. HAL currently screens at market cap $19.05B and trailing P/E 9.3.
Not investment advice. Open the ESPR and HAL stock pages for the full models.
Not investment advice.